Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients - Université de Lorraine Access content directly
Journal Articles Inflammatory Bowel Diseases Year : 2022

Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients

Abstract

Lay Summary The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.
No file

Dates and versions

hal-04168130 , version 1 (21-07-2023)

Identifiers

Cite

Luca Massimino, Salvatore Spanò, Luigi Antonio Lamparelli, Davide Fuggetta, Laurent Peyrin‐biroulet, et al.. Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients. Inflammatory Bowel Diseases, 2022, 28 (6), pp.971-976. ⟨10.1093/ibd/izab349⟩. ⟨hal-04168130⟩
17 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More